Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Single-Arm, Open-Label Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes (PRO) of Giredestrant in Patients With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy

NCT07541079 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT07541079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07541079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Single-Arm, Open-Label Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes (PRO) of Giredestrant in Patients With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
August 25, 2026
Completion date
June 30, 2034
Enrollment
300 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

early breast cancer